- Home
- CNSP vs ALZN Comparison
CNSP vs ALZN Comparison
Compare CNSP & ALZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNSP
- ALZN
- Stock Information
- Founded
- CNSP 2017
- ALZN 2016
- Country
- CNSP United States
- ALZN United States
- Employees
- CNSP N/A
- ALZN N/A
- Industry
- CNSP Biotechnology: Pharmaceutical Preparations
- ALZN Medicinal Chemicals and Botanical Products
- Sector
- CNSP Health Care
- ALZN Health Care
- Exchange
- CNSP Nasdaq
- ALZN Nasdaq
- Market Cap
- CNSP 5.6M
- ALZN 6.1M
- IPO Year
- CNSP 2019
- ALZN 2021
- Fundamental
- Price
- CNSP $1.25
- ALZN $1.04
- Analyst Decision
- CNSP Hold
- ALZN Strong Buy
- Analyst Count
- CNSP 1
- ALZN 1
- Target Price
- CNSP N/A
- ALZN $20.00
- AVG Volume (30 Days)
- CNSP 332.7K
- ALZN 212.9K
- Earning Date
- CNSP 05-14-2025
- ALZN 03-10-2025
- Dividend Yield
- CNSP N/A
- ALZN N/A
- EPS Growth
- CNSP N/A
- ALZN N/A
- EPS
- CNSP N/A
- ALZN N/A
- Revenue
- CNSP N/A
- ALZN N/A
- Revenue This Year
- CNSP N/A
- ALZN $322.64
- Revenue Next Year
- CNSP N/A
- ALZN N/A
- P/E Ratio
- CNSP N/A
- ALZN N/A
- Revenue Growth
- CNSP N/A
- ALZN N/A
- 52 Week Low
- CNSP $1.21
- ALZN $0.64
- 52 Week High
- CNSP $800.00
- ALZN $15.06
- Technical
- Relative Strength Index (RSI)
- CNSP 30.28
- ALZN 58.05
- Support Level
- CNSP $1.28
- ALZN $0.95
- Resistance Level
- CNSP $1.46
- ALZN $1.13
- Average True Range (ATR)
- CNSP 0.38
- ALZN 0.10
- MACD
- CNSP -0.12
- ALZN 0.02
- Stochastic Oscillator
- CNSP 1.18
- ALZN 81.52
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.